GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: BCD 132 | BCD-132 | Ivlizi®
                                 divozilimab is an approved drug (Russia (2023)) Compound class: 
                                                            Antibody
                                 
                                    
                                        Comment: Divozilimab (BCD 132) is an anti-CD20 monoclonal antibody that was developed by Biocad.
                                    
                                 | 
| Classification  | |
| Compound class | Antibody | 
| Approved drug? | Yes. Russia MinzDRAV (2023) | 
| International Nonproprietary Names  | |
| INN number | INN | 
| 11336 | divozilimab | 
| Synonyms  | 
| BCD 132 | BCD-132 | Ivlizi® | 
| Database Links  | |
| Specialist databases | |
| IMGT/mAb-DB | 1060 | 
| Other databases | |
| GtoPdb PubChem SID | 491299869 | 
| Search PubMed clinical trials | divozilimab | 
| Search PubMed titles | divozilimab | 
| Search PubMed titles/abstracts | divozilimab |